The clinical significance of Fibrinogen plasma levels in patients with diffuse large B cell lymphoma

Journal of Clinical Pathology

Volumn 69, Issue 4, 2016, Pages 326-330

  Troppan, Katharina T ^a   Melchardt, Thomas ^b   Wenzl, Kerstin ^a   Schlick, Konstantin ^b   Deutsch, Alexander ^a   Bullock, Marc D ^c   Reitz, Daniel ^a   Beham Schmid, Christine ^a   Weiss, Lukas ^b   Neureiter, Daniel ^b   Tränkenschuh, Wolfgang ^b   Greil, Richard ^b   Neumeister, Peter ^a   Egle, Alexander ^b   Pichler, Martin ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; FIBRINOGEN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84954304808     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-203356     Document Type: Article

References (47)

1. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-29.
2. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010;60:393-408.
3. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
4. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61.
5. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-42.
6. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
7. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
8. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
9. Troppan K, Deutsch A, Gerger A, et al. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer 2014;110:369-74.
10. Groblewska M, Mroczko B, Sosnowska D, et al. Interleukin 6 and C-reactive protein in esophageal cancer. Clin Chim Acta 2012;413:1583-90.
11. Poole EM, Lee IM, Ridker PM, et al. A Prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor a receptor 2 levels and risk of ovarian cancer. Am J Epidemiol 2013;178:1256-64.
12. Ramsey S, Lamb GW, Aitchison M, et al. The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer 2006;95:1076-80.
13. Purdue MP, Hofmann JN, Kemp TJ, et al. A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. Blood 2013;122:951-7.
14. Pichler M, Hutterer GC, Stojakovic T, et al. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 2013;109:1123-9.
15. Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 2013;108:901-7.
16. Son HJ, Park JW, Chang HJ, et al. Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol 2013;20:2908-13.
17. Ghezzi F, Cromi A, Siesto G, et al. Prognostic significance of preoperative plasma fibrinogen in endometrial cancer. Gynecol Oncol 2010;119:309-13.
18. Yamashita H, Kitayama J, Nagawa H. Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol 2005;35:595-600.
19. Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol 2001;106:33-42.
20. Qi Q, Geng Y, Sun M, et al. Hyperfibrinogen is associated with the systemic inflammatory response and predicts poor prognosis in advanced pancreatic cancer. Pancreas 2015;44:977-82.
21. Wang J, Liu H, Shao N, et al. The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma. World J Surg Oncol 2015;13:157.
22. Sun ZQ, Han XN, Wang HJ, et al. Prognostic significance of preoperative fibrinogen in patients with colon cancer. World J Gastroenterol 2014;20:8583-91.
23. Zhao K, Deng H, Qin Y, et al. Prognostic significance of pretreatment plasma fibrinogen and platelet levels in patients with early-stage cervical cancer. Gynecol Obstet Invest 2015;79:25-33.
24. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-32.
25. Troppan KT, Schlick K, Deutsch A, et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer 2014;111:55-60.
26. Troppan KT, Melchardt T, Deutsch A, et al. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol 2015. Feb. 13. doi:10.1111/ejh.12529. [Epub ahead of print].
27. Absenger G, Szkandera J, Pichler M, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013;109:395-400.
28. Shepshelovich D, Ram R, Uziel O, et al. MicroRNA signature is indicative of long term prognosis in diffuse large B-cell lymphoma. Leuk Res 2015;39:632-7.
29. Ilhan-Mutlu A, Starlinger P, Perkmann T, et al. Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer. Biomark Med 2015;9:327-35.
30. Liu YL, Lu Q, Liang JW, et al. High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer. Medicine 2015;94:e481.
31. Thurner EM, Krenn-Pilko S, Langsenlehner U, et al. The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients. World J Urol 2015;33:1467-73.
32. Kim KH, Park TY, Lee JY, et al. Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer. J Korean Med Sci 2014;29:507-11.
33. Pichler M, Dalpiaz O, Ehrlich GC, et al. Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 2014;191:920-5.
34. Szkandera J, Pichler M, Liegl-Atzwanger B, et al. The elevated pre-operative plasma fibrinogen level is an independent negative prognostic factor for cancer-specific, disease-free and overall survival in soft-tissue sarcoma patients. J Surg Oncol 2014;109:139-44.
35. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
36. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-9.
37. Schoppmann SF, Birner P, Stöckl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-56.
38. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
39. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-9.
40. Ribatti D, Ennas MG, Vacca A, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003;33:420-5.
41. Trousseau A. Phlgmasia Alba Dolens. Clinique Medicale de l'Hotel Dieu de Paris. Vol 3. 2nd edn. Paris: JB Baillere, 1865: © 659-712.
42. Buller HR, van Doormaal FF, van Sluis GL, et al. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007;5(Suppl 1):246-54.
43. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7.
44. Pabinger I, Ay C. Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis? Haemostaseologie 2012;32:132-7.
45. Danesh J, Lewington S, Thompson SG, et al, Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809.
46. Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994;71:719-22.
47. Königsbrügge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res 2014;133(Suppl 2):S39-43.